News

The acquisition provides Abbott with a biologic intended to treat multiple sclerosis (MS) and compounds that complement its existing diverse oncology program. The new Abbott compounds include daclizumab,

Reportedly, the current CEO of Bayer HealthCare, Arthur Higgins, is expected to leave the company on April 30, 2010 . Werner Wenning, chairman of the board of management

The project’s collaborators include various small-and-medium enterprises (SMEs), multinational corporations, the public sector and the Universities of Glasgow, Edinburgh, Strathclyde and Heriot-Watt. The investment is expected to position

MMR said that these antibody assets may be used in the development of future treatment options for various autoimmune and B-Cell mediated diseases, which could include lupus nephritis,

Xerecept is an investigational new drug that may present an alternative to dexamethasone for patients with primary and metastatic brain tumors. Xerecept has shown in Phase II and

Comparing treatment with the Delcath PHP System with melphalan to Best Alternative Care (BAC), based on independent core lab review of patient scans, the statistical analysis revealed that

Medtronic Complete SE Vascular Stent System features several advances, including a dual-deployment delivery system with a triaxial design. The new delivery system is made up of an inner

The issued patent covers Mystic Pharmaceuticals’ proprietary unit dose blister technology for packaging of drugs or biologics that have been freeze dried to powder form to improve stability,

Sinclair Pharmacy is expected to work in conjunction with Syntopix to develop a product. Should the collaboration result in a product that reaches commercialisation, financial gains from the